Log In
BCIQ
Print this Print this
 

Oral budesonide suspension (OBS) (SHP621)

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionOral viscous formulation of budesonide
Molecular Target Corticoid receptors
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationEosinophilic esophagitis
Indication DetailsTreat eosinophilic esophagitis (EoE); Treat pediatric eosinophilic esophagitis
Regulatory Designation U.S. - Breakthrough Therapy (Treat eosinophilic esophagitis (EoE));
U.S. - Orphan Drug (Treat eosinophilic esophagitis (EoE))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$245.0M

$70.0M

$175.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/24/2015

$245.0M

$70.0M

$175.0M

Get a free BioCentury trial today